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This review discusses the rational for further studies of COX-2 inhibitors-NO releaser hybrids (NO-
Coxibs) in the pharmacological treatment of the airway inflammation in Cystic Fibrosis (CF). Our research
group developed several classes of NO-Coxibs for the pharmacological treatment of arthritis, and among
them several compounds showed an outstanding in vivo efficacy and good pharmacokinetic properties.
The good antiinflammatory properties displayed by these compounds during the previous screening
could, by itself, suggest appropriate candidates for further testing in CF.
© 2020 Elsevier Masson SAS. All rights reserved.1. Introduction
Cystic fibrosis (CF) is one of the most common genetic inherited
life-shortening disease affecting Caucasian population. It is caused
by mutations in the gene of the cystic fibrosis transmembrane
regulator (CFTR), a cAMP-dependent anion channel mostly
expressed in the apical membrane of epithelia cells [1,2]. Therefore,
the primary defect in CF patients is a reduction in chloride and
bicarbonate transport capacity across the apical membrane of
epithelial cells, which in turn impacts on water secretion and so-
dium concentration, altering the characteristics of the secreted
fluids [3]. The most common CFTR mutation found in CF patients is
F508CFTRdel. This deletion results in a loss of the phenylalanine at
position 508 of the protein, which prevents the protein from
folding efficiently and affects the function and processing of the
CFTR molecules [4]. Although, the shortened life expectancyBiava).
served.
, C. Ghelardini et al., Therapeu
ttps://doi.org/10.1016/j.ejmecaccompanying the disease can most often be attributed to pulmo-
nary complications [5], patients with CF also suffer from a variety of
systemic complications including dysfunction of the gastrointes-
tinal (pancreas and liver), renal, immune, endocrine and male
genital systems [6,7]. In the lungs CFTR dysfunction is associated
with loss of the critical hydration of the airway surface, abnormal
mucin secretion, epithelial cell vulnerability and with dysregula-
tion of the local inflammatory responses, resulting in excessive
airway neutrophilic inflammation and pathogen growth [8]. The
resulting dysregulation of defence function followed by persistent
bacterial infections gives rise to airway damage and remodelling,
leading to severe lung deficiency [9,10].1.1. Inflammation in CF
In the past, the combination of mucus obstruction and infection
was believed to drive the exaggerated and dysfunctional inflam-
matory response, which leads to irreversible airway destruction
and fibrosis and hence to severe lung damage, the main cause of
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children with CF, even in the absence of respiratory infections,
suggesting that the disease itself might be related to anomalous
inflammatory responses [11]. Moreover, it has been reported how
CFTR defects in CF contribute to endogenous activation of NF-kB,
and to the exaggerated production of the pro-inflammatory cyto-
kines IL-1b, IL-6, IL-8 and TNF-a, even in the absence of bacterial
infections [12e14]. In addition to increased release of pro-
inflammatory cytokines, it was also demonstrated an over-
production of PGE2 and other prostanoids in patients with CF [15].
Cyclooxygenase (COX) represents the key enzyme in arachidonic
acid metabolism, converting arachidonic acid to prostaglandin H2
(PGH2). COX consists of two isoforms: COX-1 and COX-2. The
constitutively expressed COX-1 exerts housekeeping functions in
most tissues maintaining the homeostasis. Inhibition of COX-1 re-
duces platelet thromboxane B2 and PGE2 production in several
tissues. Even though COX-1 may contribute to the total pool of
prostaglandins at the site of inflammation, its contribution to
inflammation is at the present not fully understood. Conversely,
COX-2 is induced, in response to inflammatory cytokines, in various
cell types (including monocytes/macrophages). Since this isoform
is notably activated by pro-inflammatory stimuli and presents
mainly a pro-inflammatory function, it was highlighted as the most
important player in inflammatory processes. COX-2 is considered
the main target for NF-kB activation, a key factor in the dysregu-
lation of the innate immune and host inflammatory response [16].
It is well known how the mutations in CFTR influence the lung
epithelial innate immune function leading to exaggerated and
ineffective airway inflammation that fails to abolish pulmonary
pathogens and gives rise to structural damage of the airways
impairing lung function and ultimate leading to respiratory failure
and death [10]. It was recently shown, how the reduction of COX
protein levels (mainly COX-2) had a positive effect on all analysed
clinical parameters. This suggests an important role of the inhibi-
tion of arachidonic acid conversion into prostaglandins which, by
reducing the inflammatory process, acts as protective modifier of
pulmonary disease in CF patients [17,18].
With the recognition that airway inflammation plays a signifi-
cant pathogenic role in CF, modulation of the inflammatory
response has become a significant therapeutic target and drugs that
target inflammation have been shown to slow the decline in lung
function and improve survival [19,20]. Corticosteroid administra-
tion showed positive effects on lung function; however, the
accompanying adverse effects led to premature discontinuation of
clinical trials. Ibuprofen, a COX-1/COX-2 inhibitor, is the only anti-
inflammatory drug currently recommended for the long-term
treatment of CF airway inflammation [21]. In animal models of
chronic infection, high-dose ibuprofenwas demonstrated to reduce2
inflammation without hindering bacterial clearance. This led to
clinical trials which demonstrated a benefit in slowing the pro-
gression of lung disease in CF. However, concerns about adverse
effects have limited the use of high-dose ibuprofen in CF patients.
Interestingly, it was observed that ibuprofen at the high clinically
relevant doses can suppress transcriptional activity of NF-kB and
other pro-inflammatory transcription factors [22]. High-dose
ibuprofen can also enhance the function of F508delCFTR and it
corrects CFTR function [23].
1.2. CFTR correctors and potentiators
In addition to therapeutics that have been developed to treat the
symptoms of CF, more recent research has been focused on the
development of therapies targeting the root cause of CF, identifying
suitable compounds that could reverse the CFTR molecular defect
and prevent the progression of CF disease [24]. Recent studies have
revealed that inhibition of F508delCFTR ubiquitination and pro-
teasomal degradation with chemical or pharmacological chaper-
ones promotes its correct folding and channel function. Thus,
pharmacological strategies that increase the maturation of the
mutant CFTR (correctors) [25] and/or potentiate channel conduc-
tance (potentiator) [26] should be beneficial to the majority of CF
patients. The knowledge of the CFTR molecular target, the devel-
opment of appropriate pharmacological tests along with high-
throughput screening led to the success in partial pharmacologic
restoration of CFTR activity. However, the currently available clin-
ical data suggest that this therapy will require combinations of
CFTR correctors and potentiator exploiting different mechanisms of
action with additive/synergistic efficacies. A few small molecules
targeting mutant CFTR are available for CF patients: lumacaftor
(VX-809) (corrector) and ivacaftor (VX-770) (potentiator) along
with the corresponding combination therapy [27,28]. Unwanted
side effects and drug interactions of lumacaftor have recently been
overcame with the development of tezacaftor (VX-661) [29,30].
Recently, a triple combination of two correctors, elexacaftor (VX-
445) and tezacaftor, and a potentiator (ivacaftor) has been
approved for the treatment of CF patients carrying the F508del-
CFTR mutation [31e33]. Despite these progresses many CF pa-
tients still await more effective drug treatments [34].
1.3. Nitric oxide and CF
Nitric Oxide (NO), formed from L-arginine by NO synthases
(NOS-1,2,3) has been shown to play an essential role in a variety of
biological processes in the lung, including bronchodilation,
inflammation and host-defence against pathogens [35e37]. NOS1
derived NO is a neurotransmitter and is involved in human
S. Consalvi, G. Poce, C. Ghelardini et al. European Journal of Medicinal Chemistry xxx (xxxx) xxxbronchomotor control. Its anomalous activity contributes to the
development of airway obstruction. In the lung NOS2 is expressed
by macrophages, neutrophils and bronchial epithelial cells and
manly acts as antimicrobial agent. NOS3 is constitutively expressed
in pulmonary blood vessels, airway epithelial cells and neutrophils.
There is increasing evidence that NOS3 contributes to NO related
patho-physiology in the airways [38].
Although NO concentration in exhaled air is generally increased
in inflammatory lung diseases like asthma and bronchiectasis, in CF
patients it is not increased, or even decreased. Moreover, in upper
airways NO is significantly lower in CF patients than in controls
[39]. The reasons for this NO deficiency may include reduced
expression of NOS, as well as lower availability of L-arginine [40].
Therapeutic interventions aiming at correcting the NO deficiency in
CF patients are therefore currently being explored as new therapies
for this disease. A clinical study assessing the safety and efficacy of
inhaled NO as adjuvant therapy in CF patients was reported [41].
However, the hazards of pressurized cylinders and toxicity con-
cerns have led researchers to develop and study the utility of NO
donors. For example, the cephalosporin (NO)-donor prodrug DEA-
C3D designed to deliver NO to bacterial infection sites, selectively
releases NO in response to contact with bacterial b-lactamase [42].
Several carbonic anhydrase inhibitors NO-donors have shown good
ability in reducing elevated intraocular pressure in an animalmodel
of ocular hypertension for the treatment of glaucoma [43e45].
Alginate biopolymers can be chemically modified to store and
release NO. The resulting N-diazenium diolate alginate NO donors
showed in aqueous solution NO-release kinetics able to produce
therapeutic NO levels. In particular, the generated NO showed
bactericidal activity against Pseudomonas aeruginosa and Staphy-
lococcus aureus and other strains relevant to CF [46,47]. S-nitro-
sothiols (SNOs), which can be formed by reaction of NO with thiols,
are endogenous cell signalling molecules present in the lung
[48e50]. Despite the physiological importance, low concentrations
of SNOs were found in CF patients [51]. It was reported that S-
nitrosoglutathione (GSNO) increases cellular expression, matura-
tion, and function of CFTR in human airway epithelial cell cultures
expressing mutant F508del CFTR [52]. These actions reflect in a
clinical efficacy in CF patients treated with GSNO [53,54]. More
recently, it was reported how this effect is common also with other
SNOs [55]. Therefore, the ability of SNOs to augment thematurationFig. 1. Perspective on the rationale of u
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and stability of the CFTR could be helpful on the treatment of CF,
and there is growing interest in more bioavailable and stable NOSs
compounds or corresponding precursors as a novel class of
corrector therapies for CF (Fig. 1).1.4. COX-inhibiting nitric oxide donors (CINODs)
Among all the mediators participating in the inflammation
process, prostaglandins remain the major target of anti-
inflammatory therapies since nonsteroidal anti-inflammatory
drugs (NSAIDs) have been discovered. NSAIDs are also widely
used to treat the inflammatory pain and act by inhibiting COX
isoforms. As discussed in paragraph 1.2, the COX isoforms catalyse
the conversion of arachidonic acid to prostanoids, but with differ-
ences in terms of expression, function and structure. The consti-
tutively expressed COX-1 exerts housekeeping functions in most
tissues maintaining the homeostasis. It is also important for gastric
cytoprotection. COX-2 is induced in response to inflammatory cy-
tokines giving rise to a massive release of PGE2, and it is the main
player in inflammation. However, COX-2 is also constitutively
expressed in some tissues (e.g. kidney, endothelial cells and brain)
where its products PGE2 and prostacyclin (PGI2) are involved in
diverse physiological functions including renal haemodynamic and
the control of blood pressure along with endothelial thrombore-
sistance. COX-1 and COX-2 enzymes share about 60% sequence
identity and are characterized by similar three-dimensional struc-
tures. However, the COX active sites are not identical, the COX-2
binding site is more flexible and 25% larger than the one of COX-
1, with a side-pocket not present in the COX-1 isoform. These dif-
ferences in the binding site size and structure enable to develop
ligands “selective” for COX-2. All NSAIDs can inhibit COX-1 and
COX-2 in a concentration-dependent fashion. The ratio between the
50% inhibitory concentration (IC50) values for COX-1 and COX-2 is
used to describe the COX-2 selectivity of these drugs and to char-
acterize selective vs. nonselective inhibitors. The selective COX-2
inhibitors have been named coxibs while COX inhibitors with
scanty selectivity for COX-2 are referred to as traditional-NSAIDs (t-
NSAIDs). Therapy with t-NSAIDs is hampered by some side-effects
including gastrointestinal erosions and renal insufficiency. Such
critical adverse reactions aremostly dependent on COX-1 inhibition
[56]. Due to its main pro-inflammatory function, COX-2 wassing NO-Coxibs in Cystic Fibrosis.
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without gastrointestinal (GI) side-effects [57]. Consequently, coxibs
were developed to overcome the GI and renal side effects associ-
ated with the use of t-NSAIDs [58]. Later on, numerous studies of
clinical pharmacology and pharmacoepidemiology showed that
preferential inhibition of COX-2 translates into a cardiovascular
(CV) hazard [59]. The pattern of the cardiovascular effects of COX-2
inhibitors is consistent with the increased risk of coronary events
being related to a diminished restraining effect of endothelial PGI2
on platelet activation, as suggested by in-depth studies of experi-
mental thrombogenesis in COX-2-deficient mice [60]. This CV
hazard is sharedwith t-NSAIDs through the samemechanism and it
is more relevant as more is pronounced the preference for COX-2
inhibition of the drug [61].
COX-inhibiting nitric oxide donors (CINODs) was a class of drugs
initially developed to combine the pharmacological actions of a COX
inhibitor with the protective actions of NO, with the aim of reducing
the GI toxicity of the drug, while maintaining its analgesic and anti-
inflammatory effects. Naproxcinod (AZD3582)was the first in class of
this group of compounds formerly developed by NicOx [62]. As NO is
endowed with remarkable CV protective actions, being involved in
vascular smooth muscle relaxation, platelet aggregation and
thrombosis inhibition, it was speculated that NSAIDs endowed with
NO-releasing properties could also mitigate the corresponding CV
hazard. Aiming to design COX-2 selective inhibitors with improved
CV safety, NO releasing coxibs have been synthesised, in order to
compensate for the COX-2 effects on prostacyclin with NO-mediated
CV effects. Our past research has been focused on the development of
a new class of potent and selective coxibs based on the diarylpyrrole
scaffold [63e65]. Later on, we developed a class of NO-releasing
coxibs (NO-coxibs) endowed with anti-inflammatory properties
and characterized by a better cardiovascular safety profile, due to NO
antithrombotic and cardioprotective effects [66e68]. The pharma-
cokinetic of the compounds and the NO releasing properties were
also optimized in order to provide compounds with the appropriate
duration of action along with slow NO releasing properties [69e71].
Within the same timeframe, an interesting NO-releasing prodrug of
rofecoxib [72], was reported as well as nitroxy-substituted 1,5-
diarylimidazoles [73] and corresponding analogues of celecoxib
[74]. In this reviewwe discuss the rational for further studies of COX-
2 inhibitors-NO releaser hybrids (NO-Coxibs) in the pharmacological
treatment of the airway inflammation in CF. Our research group
developed several classes of NO-Coxibs for the pharmacological
treatment of arthritis, and among them several compounds showed
an outstanding in vivo efficacy and good pharmacokinetic properties.
The good antiinflammatory properties displayed by these com-
pounds during the previous screening could suggest, by itself,
appropriate candidates for further testing in CF.
2. NO-coxibs based on diarylpyrrole scaffold: nitrooxyalkyl
esters
Due to their high COX-2 inhibitory potency and selectivity, 1,5-Fig. 2. Chemical structures of Naproxcin
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diarylpyrrole-3-acetic acid (1a-d) and esters (2a-m) (Fig. 2) were
the starting point for this work. As structure-activity relationships
(SAR) of these compounds was investigated in previous works
[63e65], the substitution patterns on N1-phenyl that provided
better results were selected for this study (representative sub-
stituents: H, 3-F, 4-F, 4-OMe) as well as the preference for the p-
methylsulfonyl-phenyl moiety in the C-5 position of the pyrrole
ring. CINOD structures are characterized by a central core respon-
sible for COX inhibition with a linked NO donating moiety. In
particular, naproxcinod is the ester of naproxen with 4-(nitroxy)
butanol (NOBA) (Fig. 2). Among the possible approaches for “hy-
bridization” of our scaffold, the one consisting in the manipulation
at position-3 of pyrrole nucleus, allowed us to retain COX-2
inhibitory properties and to introduce the NO-releasing moiety.
Conversely, other scaffold manipulations led to the loss of COX-2
inhibition.
In order to test the pharmacological hypothesis of the study, the
straightforward preparation of 1,5-diarylpyrrole-3-acetic nitro-
oxyalkyl esters (3a-h) (Table 1) [66] as NO-releasing hybrids was
chosen. These compounds were designed by combining the 1,5-
diarylpyrrole moiety (compounds 1a-d) with NO-donor alkyl
chains of different length, on the basis of previous molecular
modelling considerations on different length and hindrance chains
of analogue esters 2a-m [63]. Since the nitrooxyalkyl groups are
metabolized in vivo, we also considered the corresponding hy-
droxyl derivatives (4a¡h) (Table 1) as possible metabolites. All
compounds herein described were evaluated for in vitro potency
and selectivity for COX-1 and COX-2 inhibition in a J774 murine
macrophage cell line. For selected compounds the human whole-
blood assays (WHB) was used to assess COX-1/-2 activities and
selectivity. This test is represented by WHB assay of COX isoforms
activities that exploit the constitutive and lipopolysaccharide (LPS)-
inducible COX activities of circulating platelets and monocytes, as
reflected by serum TXB2 and plasma PGE2 levels, respectively [66].
In order to evaluate NO-releasing properties the compounds were
evaluated assessing their efficacy and potency in determining NO-
vasorelaxing responses, using a model of vascular smooth muscle
relaxation (endothelium denuded rat aortic rings) [66]. In order to
confirm that the vasorelaxing effects observed were actually due to
the NO release, the experiments were also carried out in the
presence of the guanylate cyclase inhibitor 1H-[1,2,4]-oxadiazole
[4,3-a] quinoxalin-1-one (ODQ). The time dependent determina-
tion of nitrate and nitrite formation by incubation with liver ho-
mogenate was assessed as well [67,70]. For selected compounds,
in vivo anti-inflammatory and analgesic activities were evaluated in
animal models of inflammation, using the chemical visceral in-
flammatory model (pain induced by the intraperitoneal injection of
acetic acid, writhing test), and the carrageenan-induced inflam-
matory pain model [66]. Intraperitoneal injection of acetic acid
induces abdominal irritation characterized by abdominal stretch-
ing, flinching, licking, and motor incoordination. The writhing
response is due to the release of cytokines, prostaglandins, and
bradykinin, factors capable of sensitizing visceral nociceptiveod and compounds 1a-d and 2a-m.
Table 1
COX-1 and COX-2 inhibitory activity of 3a¡h, 4a¡h, and Celecoxib.





3a H 2 NO2 >10 0.043 >233
3b H 3 NO2 >10 0.042 >238
3c 3-F 2 NO2 >10 0.019 >526
3d 3-F 3 NO2 1.1 0.073 >151
3e 4-F 2 NO2 >10 0.029 >345
3f 4-F 3 NO2 >10 0.037 >269
3g 4-OCH3 2 NO2 6.4 0.170 37.6
3h 4-OCH3 3 NO2 >10 0.024 >4167
4a H 2 H >10 0.096 >104
4b H 3 H >10 >1 e
4c 3-F 2 H >10 0.085 >118
4d 3-F 3 H >10 0.023 >435
4e 4-F 2 H >10 0.039 >256
4f 4-F 3 H >10 0.056 >179
4g 4-OCH3 2 H >10 1.1 >9.1
4h 4-OCH3 3 H >10 0.7 >14.3
Celecoxib 3.84 0.061 >63
a Results are expressed as the mean (n ¼ 3 experiments) of the % inhibition of PGE2 production by test compounds with respect to control samples and the IC50 values were
calculated by GraphPad Instat program; data fit was obtained using the sigmoidal doseeresponse equation (variable slope) (GraphPad software).
b In vitro COX-2 Selectivity Index [IC50 (COX-1)/IC50(COX-2)].
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is widely used to assess the anti-inflammatory activity of several
compounds. Carrageenan is a non-antigenic phlogistic agent with
the devoid of any visible systemic effects, it contains sulphated
sugars that are liable for the activation of complement system and
the inflammatory mediators [76]. Compounds 3a-h and 4a-h were
then evaluated according to the above pharmacological protocol.
Nitrooxyalkyl esters 3a-f and 3h resulted very active and selective
COX-2 inhibitors (Table 1). They displayed better potencies and
selectivity than corresponding acids 2a-g and esters 1a-g. Depen-
dence on the side-chain length with the COX-2 inhibition potency
was highlighted in this series. Hydroxylated derivatives (4a¡h)
displayed a similar trend. The side-chain length seems to be crucial
also in determining NO-dependent vasorelaxing responses. For
compounds 3a-h strong vasorelaxing effects (pIC50 ranging be-
tween 5.47 and 6.75) (Table 2) were found only for the two-carbon
chain nitroesters (3a, 3c, 3e, 3g), while a weak activity character-
ized the three-carbon chain derivatives. The test with ODQTable 2
Efficacy and potency in determining NO-dependent vasorelaxing responses of 3a¡h
and GTNa.
Compd. R n Emaxb pIC50c
3a H 2 65 ± 2 5.76 ± 0.08
3b H 3 44 ± 8 <5
3c 3-F 2 69 ± 4 6.48 ± 0.06
3d 3-F 3 39 ± 1 <5
3e 4-F 2 58 ± 5 5.47 ± 0.07
3f 4-F 3 41 ± 2 <5
3g 4-OCH3 2 77 ± 2 6.75 ± 0.05
3h 4-OCH3 3 41 ± 11 <5
GTN 73 ± 2 6.90 ± 0.07
a GTN: glyceryl trinitrate.
b Emax represents the vasorelaxing efficacy, expressed as a % of the vasocon-
striction induced by the pre-administration of KCl.
c Parameter of potency is expressed as pIC50, representing log of the molar
concentration capable of inducing a vasorelaxing effect ¼ 50% of Emax.
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confirmed these vasorelaxing effects were due to the NO release.
The total loss of vasorelaxing activity of the hydroxylated de-
rivatives 4a¡h further supported the absence of contribution from
other moieties of the molecule to the CV effect. Additional exper-
iments suggested that these compounds ensured a slow NO release
suitable for the expected pharmacological action [66]. The meta-
fluorine subclass of compounds (3c-d) was selected for ex vivo and
in vivo studies. The COX-2 selectivity was assessed ex vivo for de-
rivatives 3c and the expected metabolite 4c, by the HWB assay.
Compounds 3c and 4c inhibited platelet COX-1 in a concentration-
dependent fashion, with IC50: 9.6 mM and 12.2 mM respectively.
Compounds 3c and 4c displayed similar inhibitions of monocyte
COX-2 with IC50: 3.2 mM and 1.7 mM, respectively (Celecoxib COX-1
12.5 mM; COX-2 0.54 mM). Thus, 3c was 3-fold and 4c was 7.3-fold
more potent toward COX-2 than toward COX-1; the drop in COX-
2 potency and selectivity in HWB assay versus J774 model can be
explained by the different sensitivities of mice and human COXTable 3
Effect of 3c-d, 4c-d, Celecoxib, and vehicle (CMC) in the mouse abdominal
constriction test (Acetic acid 0.6%).
Compd.a No. mice dose po, mg/kg (mmol/kg)b no. writhes
CMC 43 e 32.6 ± 2.1
3c 12 20 (42) 17.1 ± 2.3*
3c 12 40 (84) 9.4 ± 2.5*
3d 18 20 (41) 25.7 ± 2.8∧
3d 10 40 (82) 24.9 ± 2.2*
4c 8 3 (7) 26.9 ± 3.0*
4c 8 10 (23) 17.4 ± 2.9*
4c 8 20 (46) 16.2 ± 2.8*
4c 8 30 (70) 8.9 ± 2.1*
4d 10 20 (45) 25.3 ± 2.8
4d 10 40 (90) 15.6 ± 2.2*
Celecoxib 10 10 (26) 13.4 ± 2.6*
b Doses are expressed in mg/kg. The equivalent doses in mmol/kg are indicated in
parentheses. *, P < 0.01 versus vehicle-treated mice. ∧, P < 0.05.
a All compounds were administered per os 30 min before test.
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inflammatory activity for all the compounds tested (Table 3).
Despite the higher in vitro potency, all the compounds were in vivo
less potent than Celecoxib, though similar effects could be obtained
at higher doses. Findings reported for carrageenan induced
hyperalgesia and edema showed that all compounds were
endowedwith a satisfactory activity (Table 4). Overall the activity of
the compounds was remarkable, albeit not comparable to cele-
coxib. Noteworthy, compound 3c (in vitro more active than cele-
coxib) was less effective and had a shorter duration of action in the
in vivo test. The shorter duration of the pharmacological effect
suggested a possible metabolic deactivation for compound 3c and/
or other pharmacokinetic issues.2.1. NO-coxibs based on diarylpyrrole scaffold: esters, the solubility
issue
Since the pharmacokinetic issues affecting the in vivo effects
seen with compounds 3c-d, in addition to metabolism, can also be
due to absorption, the compounds’ solubility was investigated as
well. Simulated gastric fluid (SGF-without pepsin) and phosphate
buffered saline (PBS) were chosen to evaluate the solubility in acid
(pH 1.5 for SGF) and neutral conditions (7.4 pH for PBS). TheTable 4






dose mg/kg before treatment
saline CMC 62.6 ± 2.1
carrageenan CMC 61.9 ± 2.0
carrageenan 3c 20 32.6 ± 2.7
carrageenan 3c 40 29.8 ± 3.1
carrageenan 3c 100 31.9 ± 3.0
carrageenan 3d 20 62.5 ± 3.1
carrageenan 3d 40 63.2 ± 3.3
carrageenan 4c 30 31.8 ± 2.5
carrageenan 4d 20 62.6 ± 3.1
carrageenan 4d 40 61.3 ± 3.0
carrageenan Celecoxib 10 61.5 ± 3.4
aDoses are expressed in mg/kg. The equivalent doses in mmol/kg are indicated in parent
Table 5
COX-1 and COX-2 inhibitory activity of 5a-d, 6a-d, and Celecoxib.
Compd. R n X I
(
5a 4-F 1 NO2 >
5b 3-F 1 NO2 >
5c 4-F 2 NO2 >
5d 3-F 2 NO2 >
6a 4-F 1 H >
6b 3-F 1 H >
6c 4-F 2 H >
6d 3-F 2 H >
Celecoxib 3
a Results are expressed as the mean (n ¼ 3 experiments) of the % inhibition of PGE2 pro
calculated by GraphPad Instat program; data fit was obtained using the sigmoidal dosee
b In vitro COX-2 Selectivity Index [IC50 (COX-1)/IC50(COX-2)].
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solubility of 3c was < 1mM and 1.6 mM respectively in SGF and PBS;
similarly, the solubility for compound 4c was 1<mM and 1.1 mM
respectively in SGF and PBS [69]. These molecules were then
characterised by low solubility and this feature could heavily affect
their absorption. In order to increase solubility an ionisable moiety
was added to the scaffold, thus an amino group was introduced at
the a-position of the acetic side chain, since previous SAR studies
highlighted this as a favourable position for such a change [64].
Compounds 5a-d along with their corresponding derivatives 6a-
dwere prepared for exploring the approach (Table 5) [69]. The NO-
release properties of the compounds were appropriate (5a:
Emax ¼ 84.0 ± 2.0; pIC50 ¼ 5.66 ± 0.03; 5c: Emax ¼ 93.0 ± 1.0;
pIC50 ¼ 5.81 ± 0.03) [69]. As expected, the ionisable moiety
determined a remarkable increase of solubility. Solubility of 5awas
>200 mM and 70.8 mM, respectively in SGF and PBS, and solubility
for compound 5b was >200 mM and 80.0 mM, respectively in SGF
and PBS. Despite the cell-based assay for COX activity showed a
reduction in the potency for compounds 5a-d and 6a-d in com-
parison with 3c-d and 3e-f (Table 1), the writhing test highlighted
for compounds 5a and 5c (Table 6) [69] activities comparable to
those of compounds 3c-d. This finding strongly pointed out the
solubility among the causes responsible for the drop of the in vivo
activity seen with compounds 3c-3d. Compound 5a was selectedy carrageenan in the rat paw pressure testa.
after treatment volume (mL)
30 min 60 min 120 min 60 min
62.5 ± 1.8 63.4 ± 2.2 62.7 ± 2.5 1.33 ± 0.07
33.7 ± 2.6 35.1 ± 2.3 34.8 ± 2.3 2.44 ± 0.08
40.1 ± 3.4 35.3 ± 2.8 ND 2.52 ± 0.06
54.1 ± 3.7* 38.7 ± 3.1 ND 2.17 ± 0.08*
57.2 ± 3.5* 36.5 ± 3.8 ND 1.88 ± 0.08*
43.2 ± 3.2 45.1 ± 3.7∧ 40.7 ± 2.6 2.05 ± 0.08∧
45.5 ± 3.7* 44.9 ± 4.2∧ 36.8 ± 3.8 1.96 ± 0.09*
55.7 ± 3.1* 52.3 ± 2.8* 39.3 ± 3.5 2.51 ± 0.05
41.2 ± 3.0 45.8 ± 3.6∧ 36.4 ± 3.1 ND
43.1 ± 3.6 48.8 ± 3.6* 44.4 ± 3.3∧ ND
54.3 ± 3.9* 57.1 ± 4.0* 54.9 ± 3.6* 1.36 ± 0.07*
heses. *, P < 0.01 versus vehicle-treated mice. ND, not determined. ∧, P < 0.05.
C50 (COX-1)
mM)a










duction by test compounds with respect to control samples and the IC50 values were
response equation (variable slope) (GraphPad software).
Table 6
Effect of 5a and 5c and vehicle (CMC) in the mouse abdominal constriction test
(Acetic acid 0.6%).
Compounda Dose per p.o.b N. writhes % of writhes reduction
mg/kg mmol/kg
CMC 33.4 ± 2.5 e
5a 3 5.5 26.9 ± 2.6 19.0
10 18.4 21.3 ± 2.5* 36.2
20 36.8 18.1 ± 3.0* 46.1
40 73.6 13.5 ± 2.8* 59.6
5c 20 35.9 24.5 ± 3.2 26.9
40 71.8 19.8 ± 2.4* 40.7
b Doses are expressed in mg/kg. The equivalent doses in mmol/kg are indicated in
parentheses. *, P < 0.01 versus vehicle-treated mice. ∧, P < 0.05.
a All compounds were administered per os 30 min before test.
S. Consalvi, G. Poce, C. Ghelardini et al. European Journal of Medicinal Chemistry xxx (xxxx) xxxfor the carrageenan test: its in vivo activity (Table 7) was equivalent
to the one of compound 3c, more potent in vitro. However, the
duration of action of 5a is still shorter than celecoxib, pointing out
the presence of a metabolic issue as well.2.2. NO-coxibs based on diarylpyrrole scaffold: amides
Though the metabolism of the nitroxy derivatives may be
complex, the pathway leading to the hydroxylated derivatives is
widely considered as the most usual metabolic destiny of organic
nitrates [77]. However, for naproxcinod and related CINODs, the
esterase mediated hydrolysis into the NSAID scaffold and NOBA,
followed by further metabolic conversion of the nitroester was
proved to be the major metabolic pathway [78]. Accordingly, the
hydrolysis of alkyl esters into the corresponding acid and nitroxy
alcohol could be expected also for compounds 3a-h. Since the
enzymatic liability of the esters, was considered to be a remarkable
factor in the gap between in vitro and in vivo pharmacological
profiles of the compounds discussed at paragraph 2.1, four different
groups of compounds (Table 8) were generated through replace-
ment of the ester moiety with the amide group, in order to address
the structural issues impacting both stability and solubility [68,71].
Firstly, a class of “simple” amides obtained through the
replacement of the ester moiety with the amide group was
explored. The diarylpyrrole-3-acetic scaffold was retained and the
substitution pattern as well as the side-chain length were based on
the previously discussed SAR. Compounds 7a-d and the expected
metabolites 8a-d (Table 8) were synthesised and tested. Amide
derivatives (7a-d) displayed a COX-2 inhibition ranging from 0.25
to 0.31 mM, and the corresponding hydroxylated analogues (8a-d)
highlighted a COX-2 inhibition ranging from 0.045 to 0.30 mM. The
NO-releasing properties for compounds 7a-c are reported in
Table 9. While compound 7a showed low vasorelaxing effect,
compounds 7b and 7cwere endowedwith good efficacy, with pIC50Table 7
Activity of compound 5a and Celecoxib in the carrageenan-induced inflammationa.
Pre-treatment ipl Treatment p.o. Dose Before treatment Paw-p
After
15 mi
Saline CMC e 61.2 ± 2.5 65.6 ±
Carrageenan CMC e 36.1 ± 3.3 32.8 ±
Carrageenan 5a 20 33.8 ± 2.8 40.2 ±
Carrageenan 5a 40 32.9 ± 3.0 45.4 ±
Carrageenan Celecoxib 10 31.7 ± 2.7 45.7 ±
aDoses are expressed in mg/kg. The equivalent doses in mmol/kg are indicated in parent
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spanning from 5.78 (7b) to 5.31 (7c). ODQ antagonized the vaso-
relaxing activity of these compounds.
In the second group of compounds (Table 8), in addition to the
replacement of the ester moiety with the amide group, a carbox-
ylate group was added to the a-position of the acetic moiety in
order to increase solubility. The corresponding serine/homoserine
derivatives 9a-d and 10a-d were synthesised and tested [71]. The
homoserine derivatives were in general more potent in COX-2 in-
hibition than the corresponding serine derivatives, with IC50
ranging from 0.14 to 1.6 mM, the corresponding hydroxylated de-
rivatives (10a-d) were effective in the range IC50 0.068e0.16 mM.
However, 9a-d produced unsatisfactory vasorelaxing effects
(Table 9), probably due to the presences of the unfavourable
carboxylate moiety. In the third group of compounds (Table 8), in
addition to the introduction of the amide group, an amino group
was added to the a-position of the acetic moiety to increase solu-
bility. The derivatives 11a-b and corresponding possible metabo-
lites 12a-b were synthesised [71]. A good activity for COX-2
inhibition was found for both the compounds with the higher po-
tency for 11a (IC50 ¼ 0.054 mM). Interestingly, the hydroxylated
derivative 12a lacked any relevant COX inhibitory activity, while
12bwas effective (IC50 ¼ 0.047 mM). The introduction of the amide
group within the glycine skeleton, did not compromise the NO-
mediated vasorelaxing effects. Compounds 11a and 11b exhibited
high levels of vasorelaxing efficacy and good potencies, with
pIC50 ¼ 6.38 for both compounds (Table 9). ODQ significantly
antagonized the vasorelaxing activity.
Compounds 13a-b and 14a-b (Table 8) form the fourth group: in
addition to the replacement of the ester moiety with the amide
group, the compounds were manipulated in the 5-phenyl ring
where the 4-sulfonyl moiety was replaced with the 4-sulfamoyl
group to increase solubility [68]. However, COX-2 inhibitory po-
tency for these compounds was rather low (IC50 > 10 mM) although
the NO releasing properties were appropriate.
The selectivity for COX-2 inhibition was also assessed using the
HWB assays for the most effective compounds 7c and 11a, along
with the derivatives 8c and 12a [71]. Compound 7c displayed a
concentration-dependent inhibition of COX-1 and COX-2 with IC50
of 0.6 and 1.7 mM, respectively. Its derivative 8c, inhibited COX-2
and COX-1 activities with similar IC50: 1.4 and 1.9 mM, respec-
tively. Thereby, in the HWB assay 7c and its metabolite 8c proved to
be non-selective COX inhibitors (SI ¼ 0.3). On the other hand,
compound 11a inhibited COX-2 and COX-1 activities in a
concentration-dependent fashion with IC50: 21 and 140 mM,
respectively. Compound 11a was then significantly more potent
towards COX-2 than COX-1 (IC50, ratio: 6.7). The corresponding
derivative 12a inhibited COX-2 activity with an IC50 value of 13.7
and was less potent in COX-1 inhibition (IC50 ¼ 300 mM) (SI ¼ 22)
[71].
The kinetics of NO-release for compounds 7c and 11a were
compared with naproxcinod [71]. The time-dependent increase ofressure Edema volume (mL)
treatment
n 30 min 45 min 60 min
3.4 58.9 ± 3.8 61.4 ± 4.1 63.6 ± 4.0 1.44 ± 0.05
2.9 30.6 ± 3.2 31.8 ± 2.2 34.8 ± 3.1 2.71 ± 0.08
3.6 43.7 ± 3.7 38.3 ± 3.1 37.1 ± 3.0 2.58 ± 0.05
3.2 50.2 ± 4.4 45.6 ± 4.3 37.5 ± 2.8 2.11 ± 0.09
4.2 52.9 ± 3.1 48.3 ± 3.4 42.5 ± 2.9 2.53 ± 0.05
heses. *, P < 0.01 versus vehicle-treated mice. ND, not determined. ∧, P < 0.05.
Table 8
COX-1 and COX-2 inhibitory activity of 7aed, 8aed, 9a-d, 10aed, 11aeb, 12a-b, 13a-b, 14a-b and Celecoxib.





7a 3-F 2 NO2 >10 0.300 >33
7b 3-F 3 NO2 >10 0.250 >40
7c 4-F 2 NO2 >10 0.249 >42
7d 4-F 3 NO2 >10 0.310 >32
8a 3-F 2 H >10 0.290 >34
8b 3-F 3 H >10 0.045 >222
8c 4-F 2 H >10 0.300 >33
8d 4-F 3 H >10 0.068 >147
9a 3-F 1 NO2 >10 0.140 >71
9b 3-F 2 NO2 >10 ND >6
9c 4-F 1 NO2 >10 0.310 >32
9d 4-F 2 NO2 >10 1.60 >6.2
10a 3-F 1 H >10 0.068 >167
10b 3-F 2 H >10 ND >10
10c 4-F 1 H >10 0.160 >62.5
10d 4-F 2 H >10 0.086 >16
11a 3-F 2 NO2 >10 0.054 >185
11b 3-F 3 NO2 >10 0.140 >71
12a 3-F 2 H >10 >10 ND
12b 3-F 3 H >10 0.047 >213
13a 4-F 2 NO2 >10 16%@ 10 mM ND
13b 3-F 2 NO2 >10 45%@ 10 mM ND
14a 4-F 2 H ND 18%@ 10 mM ND
14b 3-F 2 H ND 15%@ 10 mM ND
Celecoxib 3.84 0.061 >63
a Results are expressed as the mean (n ¼ 3 experiments) of the percentage inhibition of PGE2 production by test compounds with respect to control samples and the IC50
values were calculated by GraphPad Instat program; data fit was obtained using the sigmoidal doseeresponse equation (variable slope) (GraphPad software).
b In vitro COX-2 selectivity index [IC50 (COX-1)/IC50(COX-2)].
S. Consalvi, G. Poce, C. Ghelardini et al. European Journal of Medicinal Chemistry xxx (xxxx) xxxthe concentrations of inorganic nitrites and nitrates (stable NO
metabolites) was measured after incubation (2 h) of the com-
pounds in rat liver homogenates. The nitrite concentration for 7c
was 27.0 ± 12.1 mM, while corresponding nitrate concentration was
38.3 ± 4.3 mM. Compound 11a, in the same conditions, showed
42.9 ± 6.6 mM and 56.1 ± 16.0 mM for nitrites and nitrates respec-
tively. These data indicate that both compounds are endowed with
a slow NO-releasing rate, which is a fundamental feature for the
development of well-balanced hybrids. Conversely, Naproxcinod
exhibited after 2 h, the highest concentration (367.7 ± 11.4 mM), ofTable 9
Vasorelaxing properties for compounds 7aec, 9aed, 11a-b and 13a-b.
Compd. Emaxa pIC50b
7a 49.0 ± 2.0 NC
7b 69.0 ± 8.0 5.78 ± 0.07
7c 68.0 ± 0.5 5.31 ± 0.05
9a 18.0 ± 9.0 NC
9b 25.0 ± 2.0 NC
9c 25.0 ± 1.9 NC
9d 42.0 ± 9.0 NC
11a 74.1 ± 1.0 5.38 ± 0.20
11b 86.0 ± 2.0 5.38 ± 0.03
13a 74.9 ± 2.5 5.82 ± 0.04
13b 67.5 ± 2.3 5.49 ± 0.00
Naproxcinod 68.0 ± 3.0 6.33 ± 0.06
a Emax represents the vasorelaxing efficacy, expressed as a % of the vasocon-
striction induced by the pre-administration of KCl.
b Parameter of potency is expressed as pIC50, representing log of the molar
concentration capable of inducing a vasorelaxing effect ¼ 50% of Emax.
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nitrate and nitrites (NOx). Interestingly, the concentration of NOx
was largely due to the released nitrates (340.1 ± 5.0 mM) while a
lower concentration of nitrites was detected (27.6 ± 6.2 mM). Such a
lower ratio nitrites/NOx would suggest that only a small part of the
nitro-oxy group of naproxcinod is converted to NO and that a direct
hydrolysis to inorganic nitrate is prevalent. Indeed, NOBA is a
relatively fast NO-releasing compound, and the CV effects are
detected for a maximum of 3 h after the naproxcinod administra-
tion. Conversely, the analgesic and anti-inflammatory effects of
naproxcinod are more extended because of the long half-life (i.e.,
17 h) of naproxen, thus not assuring the GI/CV protection for the
whole duration of the COX inhibition.
Solubility of compounds was assessed in SGF and PBS (Table 10)
[71]. The replacement of the ester functionality with the amide
moiety provided in general more soluble molecules. The best sol-
ubility profile was displayed by the glycine amide 11a (>200 mM in
both SGF and PBS). Comparative stability studies of the esters 3c
and 5c with amides 7c, 9a, 11a, revealed liability of the esters toTable 10
Solubility in SGF and PBS for compounds 3c, 5c, 7a, 7c, 9c, 11a.








Stability in SGF, PBS and rat plasma for compounds 3c, 5c, 7a, 9a and 11a.
Compd. Time (min) Parent molecule remained (%)
PBS (pH 7.4) SGF (pH 1.5) Rat plasma
3c 30 74.1 80.2 0.00
60 53.6 65.7 0.00
120 0.15 42.8 0.00
5c 30 75.0 100 0.00
60 75.0 100 0.00
120 75.0 100 0.00
7c 30 100 100 100
60 100 100 100
120 100 100 100
9a 30 75 100 71
60 50 93.8 57
120 37.5 87.5 28.6
11a 30 100 100 94
60 100 100 93
120 100 100 77
S. Consalvi, G. Poce, C. Ghelardini et al. European Journal of Medicinal Chemistry xxx (xxxx) xxxhydrolysis in comparisonwith amides (Table 11). Compound 7cwas
completely resistant to hydrolysis, whereas compound 11a was
relatively more liable in rat plasma (even though after 120 min ofTable 12
Effect of 1aed, 4c, 2aed, 5c, and 3a,b and vehicle (CMC) in the mouse abdominal constr













































**P < 0.05 in comparison with CMC treated animals.
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incubation 77% of the compound was still detected).
All the nitrooxyamides were tested in the writhing test, and
highlighted a good and dose-dependent activity (Table 12) [71]. In
particular, compound 7c, and glycine derivative 11awere endowed
with the higher potency, displaying respectively 77% and 79% of
reduction at 20 mg/kg. Moreover, compound 11a displayed writhes
reduction of 56% at the dose of 10 mg/kg. The most active nitro-oxy
compounds 7c and 11awere also evaluated for their activity in the
carrageenan induced edema and hyperalgesia (Table 13) [71]. The
carrageenan induced inflammation test showed that 7c was asso-
ciated with a good but not outstanding activity. Conversely, com-
pound 11a was proved to be highly active, with a reduction of
hyperalgesia at 10 mg/kg of 80% after 30 min. The activity was
maintained for 60 min (70%) and even after 90 min a satisfactory
activity (50%) was still found.
The pharmacokinetics of the best performing compounds 7c
and 11a were assessed in rats after po and iv administration at
10 mg/kg [71]. After iv administration, 7c was detected in plasma
up to 6 h. Both 7c and 11a appear to be characterized by moderate
to high rate of clearance and high volume of distribution. Com-
pound 7c showed absolute bioavailability (24%) higher than 11a
(9%). The presence of the metabolites 8c and 12a was alsoiction test (Acetic acid 0.6%).
n. Writhes after 30 min Writhes reduction (%)
32.6 ± 2.1 e
26.8 ± 2.1** 18
20.6 ± 3.0* 37
14.7 ± 2.1* 55
33.2 ± 3.5 0
29.8 ± 3.6 8.6
22.9 ± 2.2* 30
12.2 ± 2.3* 63
7.4 ± 1.3* 77
8.1 ± 1.2* 75
27.2 ± 2.7 17
20.4 ± 2.2* 37
21.6 ± 2.8* 34
20.7 ± 3.5* 37
12.6 ± 2.7* 61
28.3 ± 2.5 12
17.1 ± 3.1* 47
16.4 ± 2.9* 50
29.2 ± 2.4 10
25.2 ± 3.3** 23
33.1 ± 3.5 0
23.2 ± 2.3* 29
16.3 ± 3.2* 50
33.7 ± 3.0 0
22.8 ± 2.7* 30
14.9 ± 2.8* 54
23.7 ± 3.0 27
13.4 ± 2.8* 59
12.9 ± 2.1* 60
25.1 ± 2.3** 23
14.2 ± 2.9* 56
6.7 ± 2.0* 79
30.5 ± 2.6 6
21.4 ± 3.7* 34
18.8 ± 3.1* 42
26.7 ± 3.3* 20.5
18.5 ± 4.2* 44.9
15.8 ± 3.7* 53.0
16.7 ± 2.5* 50.3
21.8 ± 3.5* 35.1
19.4 ± 2.9* 42.3
16.7 ± 3.5* 50.3
13.5 ± 3.0* 59
Table 13
Hyperalgesia and edema reduction in the carrageenan induced inflammation for compounds 7c and 11a in comparison with celecoxib.
pretreatment, ipl paw pressure (g)
treatment
po
dose mg/kg before treatment after treatmentb volume (mL)b
30 min 60 min 90 min 120 min 60 min
Saline CMC 61.6 ± 3.4 58.9 ± 3.8 61.4 ± 4.1 61.4 ± 4.1 61.4 ± 4.1 1.44 ± 0.05
Carrageenan CMC 36.1 ± 3.3 32.8 ± 2.9 30.6 ± 3.2 31.8 ± 2.2 31.8 ± 2.2 2.71 ± 0.08
Carrageenan 7c 20 33.8 ± 2.9 40.7 ± 3.5** 42.8 ± 3.4** 37.8 ± 2.6 37.8 ± 2.6 2.63 ± 0.05
Carrageenan 40 32.9 ± 3.3 44.2 ± 4.0* 48.3 ± 4.6 41.5 ± 3.7* 31.5 ± 2.6 2.50 ± 0.09
Carrageenan 11a 20 33.8 ± 2.9 55.2 ± 3.3* 52.1 ± 4.2* 47.3 ± 3.7* 39.5 ± 3.0 1.79 ± 0.09*
Carrageenan Celecoxib 10 31.7 ± 2.7 45.7 ± 4.2* 52.9 ± 3.1* 48.3 ± 3.4* 42.5 ± 2.9 2.53 ± 0.05*
*P < 0.01.
**P < 0.05 in comparison with CMC treated animals.
Table 15
Efficacy and potency in determining NO-dependent vasorelaxing responses of
15a¡f and GTN.a.
Compd. Emaxb pIC50c
15a 65 ± 3 5.22 ± 0.03
15b 48 ± 5 5
15c 60 ± 4 5.32 ± 0.05
15d ND e
15e 58 ± 5 5.47 ± 0.07
15f 41 ± 2 5
GNT 93 ± 2 6.90 ± 0.07
a GTN: glyceryl trinitrate.
S. Consalvi, G. Poce, C. Ghelardini et al. European Journal of Medicinal Chemistry xxx (xxxx) xxxmeasured. Compound 8c was detected in rat plasma up to 6 h after
both iv and po administrations, while 12a was detected in rat
plasma at least up to 6 h after intravenous administrations and only
up to 2 h after oral administration. For 7c, after intravenous
administration at least 39% of the parent compound was converted
into the metabolite 8c while after oral administration 99% of the
parent compound was converted into the metabolite, suggesting
that after oral administration 7c is readily metabolized to 8c. For
11a, after intravenous administration only 10% of the parent com-
pound was converted into the metabolite 12a during the 6 h of the
experiment.b Emax represents the vasorelaxing efficacy, expressed as a % of the vasocon-
striction induced by the pre-administration of KCl.
c Parameter of potency is expressed as pIC50, representing log of the molar
concentration capable of inducing a vasorelaxing effect ¼ 50% of Emax.2.3. NO-coxibs based on diarylpyrrole scaffold: ethers
In order to further increase the stability of the linker between
the scaffold and the NO releasing moiety, the corresponding ethers
15a-f (Table 14) [64,67] were prepared. The conversion of the
nitrooxyalkyl ester into the nitrooxyalkyl ethermoiety led to potent
COX-2 inhibitors. Results for compounds 15a-f, and corresponding
metabolites 16a-f, in the COX inhibition (J774 cells assay) are re-
ported in Table 14. Some of them were endowed with good NO-
donating properties (Table 15) [67] along with quite good and se-
lective COX-2 inhibitory activity ranging from low nanomolar toTable 14
COX-1 and COX-2 inhibitory activity Compounds 15 a-f, 16a-f, and Celecoxib.
Compd. R n X CO
IC5
15a H 2 NO2 >1
15b H 3 NO2 >1
15c 3-F 2 NO2 >1
15d 3-F 3 NO2 2.9
15e 4-F 2 NO2 >1
15f 4-F 3 NO2 >1
16a H 2 H >1
16b H 3 H >1
16c 3-F 2 H >1
16d 3-F 3 H 3.7
16e 4-F 2 H >1
16f 4-F 3 H >1
Celecoxib 3.8
a Results are expressed as the mean (n ¼ 3 experiments) of the % inhibition of PGE2 pro
calculated by GraphPad Instat program; data fit was obtained using the sigmoidal dosee
b In vitro COX-2 Selectivity Index [IC50 (COX-1)/IC50(COX-2)].
10micromolar values. Nitrooxyalkyl ethers 15a-f highlighted a better
COX-2 inhibitory activity with respect to derivatives 16a-f, most of
the compounds were as active as corresponding nitrooxyalkyl es-
ters. Compounds 15a (n ¼ 2, H), 15b (n ¼ 3, H), 15c (n ¼ 2, 3-F), 15d
(n ¼ 3, 3-F) emerged as low nanomolar COX-2 inhibitors. Com-
pounds 15a, 15c and 15e showed better NO-vasorelaxing responses


















duction by test compounds with respect to control samples and the IC50 values were
response equation (variable slope) (GraphPad software).
Table 16
Doseresponse results of compounds 15a¡e, 16a¡d, and Celecoxib in the Acetic
Acid Writhing Test.a.
Compd. n mice dose per os (mg/kg) no. writhes Writhes reduction (%)
Saline 6 32.4 ± 1.9 -
15a 10 10 21.2 ± 3.0∧ 35
8 20 15.5 ± 3.6* 53
15b 9 10 29.4 ± 3.0 9
10 20 21.2 ± 3.0* 35
8 40 26.8 ± 3.2∧ 17
15c 8 10 32.5 ± 3.7 0
8 20 30.3 ± 2.1 6
8 40 25.3 ± 3.6* 22
15e 8 3 28.5 ± 3.2 12
8 10 19.1 ± 2.7* 41
8 20 15.2 ± 3.3* 53
16a 8 10 21.2 ± 3.0* 35
8 20 15.5 ± 3.6* 52
16b 9 10 29.7 ± 3.4 8
9 20 22.3 ± 2.5* 31
7 40 21.5 ± 2.3* 34
16c 8 10 29.4 ± 3.0 9
8 20 26.8 ± 3.2∧ 17
8 40 17.3 ± 3.5* 47
16e 7 10 31.3 ± 2.7 3
8 20 27.9 ± 3.6 14
8 40 18.1 ± 3.1* 44
Celecoxib 10 1 25.6 ± 3.1* 21
11 3 15.4 ± 2.5* 52
15 10 11.3 ± 2.9* 65
aEach value represents the mean of at least seven mice: (∧) P < 0.05.
(*) P < 0.01 in comparison with CMC treated group.
S. Consalvi, G. Poce, C. Ghelardini et al. European Journal of Medicinal Chemistry xxx (xxxx) xxxconfirming what previously shown in terms of dependence of the
activity with side chain length. Experiments with ODQ confirmed
the vasorelaxing effects were due to the NO release. COX-2 inhi-
bition was assessed ex vivo by the HWB assay for compounds 15e
and 16e [66]. Concentrationresponse curves for inhibition of COX-
1 and COX-2 in HWB showed compound 15e and its derivative 16e
inhibited LPS induced PGE2 generation (COX-2 assay) in a
concentration-dependent fashion with IC50 values respectively of
0.64 and 0.44 mM. Compounds 15e and 16e also showed compa-
rable IC80 values (respectively 2.26 and 2.31 mM). These results
pointed out that 15e and its metabolite 16e gave a comparable andTable 17




Compd. dose mg/kg before treatment after tre
30 min
Saline CMC e 62.6 ± 2.4 61.5 ± 3
Carrageenan CMC 31.4 ± 3.4 34.8 ± 3
Carrageenan 15a 20 33.9 ± 3.1 54.2 ± 3
Carrageenan 15b 10 34.1 ± 2.7 55.1 ± 4
Carrageenan 20 32.0 ± 3.5 56.8 ± 3
Carrageenan 15c 20 34.6 ± 3.0 43.9 ± 3
Carrageenan 40 31.6 ± 2.7 47.3 ± 4
Carrageenan 16a 20 32.7 ± 3.7 44.6 ± 4
Carrageenan 40 35.2 ± 3.1 49.5 ± 3
Carrageenan 16b 20 33.8 ± 3.8 52.9 ± 3
Carrageenan 16c 20 32.7 ± 3.9 46.9 ± 3
Carrageenan 40 33.5 ± 3.9 51.4 ± 3
Carrageenan 16e 20 32.5 ± 3.4 46.8 ± 3
Carrageenan 40 30.5 ± 3.5 57.2 ± 4
Carrageenan Celecoxib 3 31.7 ± 2.7 44.3 ± 3
Carrageenan 10 33.5 ± 2.6 52.9 ± 3
(∧) P < 0.05, (*) P < 0.01 versus the carrageenan/saline-treated group.
11potent inhibitory effect on COX-2 activity in HWB. Furthermore,15e
and 16e inhibited platelet COX-1 activity in a concentration-
dependent fashion; 16e was slightly more potent (IC50 ¼ 20.0;
IC80 ¼ 37.14) in COX-1 inhibition than 15e (IC50 ¼ 31.24;
IC80 ¼ 63.3). Thus, both compounds were proved to be selective,
being 50-fold more potent toward COX-2 than COX-1 at IC50.
Compounds 15a-f, and corresponding hydroxylated derivatives
were evaluated in vivo, both in the writhing test and in the
carrageenan-induced inflammatory pain model [66]. In the
writhing test the minimal dose able to revert the painful condition
was 10mg/kg po for 15a,15e and 16a, 20mg/kg for 15b,16b, 40mg/
kg for 15c and 16e (Table 16). In the carrageenan inflammatory pain
model all the tested molecules were effective in the range between
40 and 20 mg/kg po, at 120 min, and a significant paw edema
decrease was observed 60 min after the administration for all the
investigated compounds (Table 17) [67]. At the higher tested dose,
the antihyperalgesic activity lasted up to 120 min for all the com-
pounds, except for 15a and 15b.
The incubation of 15e in rat plasmawas followed by a negligible
formation of nitrites and nitrates (3.2 ± 0.7 mM and 0.24 ± 0.24 mM,
respectively, at 120 min) while the corresponding experiment with
naproxcinod showed a massive formation of nitrate [70]. The in-
cubation of 15e in liver homogenate was followed by a slow and
time-dependent production of nitrites and nitrates; after 120 min
of incubation, the recorded concentrations were 4.6 ± 0.5 mM and
26.9 ± 3.4 mM, respectively. Naproxcinod showed a more rapid
accumulation of larger amounts of thesemetabolites (28.0 ± 6.0 mM
of nitrites and 340.1 ± 5.0 mM of nitrates, at 120 min) [70]. There-
fore, 15e exhibited the feature of “NO-reservoir”, stable in plasma
and slowly converted to NO by the cell metabolism (liver, vascular
smooth muscle, endothelium, etc.). The 15e NO-releasing proper-
ties were confirmed by the endothelium-independent vasorelaxing
effects evoked in aortic rings of normotensive rats; these effects
were antagonized by ODC. In order to determine the NO generation
in vivo and its possible effects on the progression of systolic blood
pressure (SBP),15e (20 mg/kg/day) was chronically administered to
youngmale spontaneous hypertensive rats (SHRs) [70] The effect of
the metabolite 16e was studied as well. The coxib-associated CV
adverse effects are increased when other CV disorders are already
present; therefore, 15e effect was studied when chronicallynan in the Rat Paw Pressure Test.
atment Paw volume (mL)
60 min 120 min before treatment 60 min
.1 60.2 ± 3.3 62.9 ± 3.5 1.46 ± 0.05 1.42 ± 0.07
.0 33.9 ± 3.7 31.4 ± 3.7 1.47 ± 0.07 2.48 ± 0.06
.1* 55.3 ± 3.5* 48.7 ± 3.7∧ 1.31 ± 0.09 1.45 ± 0.10*
.7* 52.6 ± 4.0* 48.3 ± 5.2∧ 1.49 ± 0.08 1.87 ± 0.07*
.9* 49.2 ± 4.6* 43.8 ± 4.5∧ 1.53 ± 0.08 1.92 ± 0.08*
.1∧ 40.7 ± 3.0 35.2 ± 3.5 1.58 ± 0.08 2.16 ± 0.09∧
.2* 41.0 ± 4.4 34.3 ± 4.1 1.55 ± 0.09 2.08 ± 0.07*
.0∧ 46.9 ± 4.2∧ 38.8 ± 3.5 1.54 ± 0.06 2.19 ± 0.07∧
.8* 42.5 ± 4.1 35.3 ± 3.8 1.48 ± 0.07 2.10 ± 0.08*
.6* 50.3 ± 2.9* 46.6 ± 3.1∧ 1.47 ± 0.05 1.86 ± 0.04*
.8∧ 48.6 ± 3.5∧ 37.2 ± 3.9 1.55 ± 0.08 2.46 ± 0.08
.0* 45.3 ± 4.4∧ 39.5 ± 4.0 1.49 ± 0.09 2.12 ± 0.06∧
.7* 38.7 ± 3.3 38.3 ± 3.9 1.57 ± 0.07 2.01 ± 0.09*
.6* 58.3 ± 4.5* 47.6 ± 4.4∧ 1.55 ± 0.09 1.95 ± 0.08*
.8* 41.6 ± 3.2 40.7 ± 2.6 1.59 ± 0.08 2.35 ± 0.07
.1* 48.3 ± 3.4* 39.8 ± 3.1 1.50 ± 0.05 1.45 ± 0.06*
S. Consalvi, G. Poce, C. Ghelardini et al. European Journal of Medicinal Chemistry xxx (xxxx) xxxadministered to SHRs, a suitable experimental model of heavy
alteration of the CV function. Indeed, in young SHRs, an age-related
progression of blood pressure is always observed and highly se-
lective COX2 inhibitors, such as rofecoxib, accelerate and worsen it.
After one month of pharmacological treatments of SHRs, serum
concentrations of nitrites and nitrates weremeasured [70]. Though,
treatment with 16e did not influence the levels of plasma nitrites
and nitrates, in the 15e-treated animals the concentration of ni-
trites was not significantly changed but a significant increase in
nitrates concentration of was observed. In the Langendorff-
perfused isolated hearts of vehicle-treated SHRs, the coronary flow
was like that recorded in normotensive animals. The coronary flow
in SHR rats treated with 15e was significantly increased while the
one of 16e-treated animals was not significantly changed. The SBP
development in 15e-treated SHRs was completely equivalent to
that of vehicle treated SHRs, while treatment with 16e (devoid of
NO releasing properties) did not accelerate the age-related increase
of SBP in young SHRs. Overall this indicates that the NO-releasing
property of 15e can significantly improve the overall CV function
and thus is a useful complementary aspect for coxibs.
3. Conclusions
Cystic fibrosis, a life-shortening disease due to mutations in CFTR
ion channel, among other complications can lead to severe lung
deficiency, characterized by chronic respiratory disease and lung
damage with persistent and exaggerated inflammation that gives
rise to irreversible airway destruction leading to morbidity and
mortality in CF patients. Therapies targeting the root cause of CF have
been recently developed, and results from several clinical trials are
available. These therapies are based on compounds that in principle
could reverse the CFTR molecular defect, preventing the CF pro-
gression. However, the available results are not completely satisfying
and at least two of these therapies must be simultaneously carried
out in order to obtain relevant clinical results. On the other hand, the
treatment of the dysfunctional inflammatory response underling the
irreversible airway destruction and fibrosis in CF has been proved
difficult with t-NSAIDs or steroidal antiinflammatory drugs. Though
several evidences suggest that COX-2 could be a remarkable target
for treating inflammation in CF, the efficacy of coxibs has not been
investigated yet, probably owing to the related side effects. Nitric
oxide plays an essential role in a variety of biological processes in the
lung. In addition, NO can stabilize CFTR and correct its disfunction by
protein nitrosylation. Despite this physiological importance, low
concentrations of NO were found in CF patients, and therapeutic
interventions aiming to correct the nitric oxide deficiency in CF pa-
tients are investigated at the present. There is a growing interest in
the class of bioavailable and stable nitrosothiols and corresponding
precursors as a novel class of corrector therapies for CF. Herein we
discussed how a suitable NO-releasing moiety endowed with
appropriate releasing rates can be conjugated to a coxib, according to
a strategy aimed at both improving drug effectiveness and moder-
ating those side effects linked to the mechanism of action of the
native drug. The efforts aimed at overcoming pharmacokinetics is-
sues related to bioavailability and stability of the compounds have
been discussed alongwith the characteristics of the products that are
suitable candidates for further development. Taking together the
topics discussed above it appears that the best performing com-
pounds (11a in the amide and 15e in the ether classes) can be good
candidates to treat CF according to a new and promising approach.
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